Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived peptide epitopes

Walter J. Storkus, Christopher Herrem, Mayumi Kawabe, Peter A Cohen, Ronald M. Bukowski, James H. Finke, Amy K. Wesa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Tumors represent an "altered" self cell type that can be recognized by both the host humoral (B cells, antibodies) and cellular (T cells) adaptive immune systems. "Because most known tumor-associated antigens (TAA) recognized by T cells represent overexpressed or aberrantly expressed proteins, which are not mutated and to which tolerance has been developed, the anti-TAA T-cell repertoire available to the cancer patient is of moderate-to-low avidity. Specific vaccinations typically amplify the absolute number of such T cells, but may have little consequence on improving their functional avidity, which may fall below a critical threshold required for effective recognition of tumor cells in situ. This review will discuss methods to improve low-avidity T-cell recognition of cancer cells by manipulating the tumor cells themselves to conditionally express higher levels of TAA-derived peptide epitopes presented in major histocompatibility (MHC) complexes. This may facilitate the design and performance of novel combinational therapies for the effective treatment of a broad range of cancer types.

Original languageEnglish (US)
Pages (from-to)485-493
Number of pages9
JournalCritical Reviews in Immunology
Volume27
Issue number5
StatePublished - 2007
Externally publishedYes

Fingerprint

Histocompatibility
Neoplasm Antigens
Immunotherapy
Epitopes
Peptides
Neoplasms
B-Lymphocytes
Antibodies
T-Lymphocytes
Major Histocompatibility Complex
Immune System
Vaccination
Therapeutics
Proteins

Keywords

  • Antigen processing
  • CD8+ T lymphocytes
  • HSP90
  • Proteasome

ASJC Scopus subject areas

  • Immunology

Cite this

Storkus, W. J., Herrem, C., Kawabe, M., Cohen, P. A., Bukowski, R. M., Finke, J. H., & Wesa, A. K. (2007). Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived peptide epitopes. Critical Reviews in Immunology, 27(5), 485-493.

Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived peptide epitopes. / Storkus, Walter J.; Herrem, Christopher; Kawabe, Mayumi; Cohen, Peter A; Bukowski, Ronald M.; Finke, James H.; Wesa, Amy K.

In: Critical Reviews in Immunology, Vol. 27, No. 5, 2007, p. 485-493.

Research output: Contribution to journalArticle

Storkus, WJ, Herrem, C, Kawabe, M, Cohen, PA, Bukowski, RM, Finke, JH & Wesa, AK 2007, 'Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived peptide epitopes', Critical Reviews in Immunology, vol. 27, no. 5, pp. 485-493.
Storkus, Walter J. ; Herrem, Christopher ; Kawabe, Mayumi ; Cohen, Peter A ; Bukowski, Ronald M. ; Finke, James H. ; Wesa, Amy K. / Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived peptide epitopes. In: Critical Reviews in Immunology. 2007 ; Vol. 27, No. 5. pp. 485-493.
@article{1190fdd4edf64e8cb114b8ac02cc7f65,
title = "Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived peptide epitopes",
abstract = "Tumors represent an {"}altered{"} self cell type that can be recognized by both the host humoral (B cells, antibodies) and cellular (T cells) adaptive immune systems. {"}Because most known tumor-associated antigens (TAA) recognized by T cells represent overexpressed or aberrantly expressed proteins, which are not mutated and to which tolerance has been developed, the anti-TAA T-cell repertoire available to the cancer patient is of moderate-to-low avidity. Specific vaccinations typically amplify the absolute number of such T cells, but may have little consequence on improving their functional avidity, which may fall below a critical threshold required for effective recognition of tumor cells in situ. This review will discuss methods to improve low-avidity T-cell recognition of cancer cells by manipulating the tumor cells themselves to conditionally express higher levels of TAA-derived peptide epitopes presented in major histocompatibility (MHC) complexes. This may facilitate the design and performance of novel combinational therapies for the effective treatment of a broad range of cancer types.",
keywords = "Antigen processing, CD8+ T lymphocytes, HSP90, Proteasome",
author = "Storkus, {Walter J.} and Christopher Herrem and Mayumi Kawabe and Cohen, {Peter A} and Bukowski, {Ronald M.} and Finke, {James H.} and Wesa, {Amy K.}",
year = "2007",
language = "English (US)",
volume = "27",
pages = "485--493",
journal = "Critical Reviews in Immunology",
issn = "1040-8401",
publisher = "Begell House Inc.",
number = "5",

}

TY - JOUR

T1 - Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived peptide epitopes

AU - Storkus, Walter J.

AU - Herrem, Christopher

AU - Kawabe, Mayumi

AU - Cohen, Peter A

AU - Bukowski, Ronald M.

AU - Finke, James H.

AU - Wesa, Amy K.

PY - 2007

Y1 - 2007

N2 - Tumors represent an "altered" self cell type that can be recognized by both the host humoral (B cells, antibodies) and cellular (T cells) adaptive immune systems. "Because most known tumor-associated antigens (TAA) recognized by T cells represent overexpressed or aberrantly expressed proteins, which are not mutated and to which tolerance has been developed, the anti-TAA T-cell repertoire available to the cancer patient is of moderate-to-low avidity. Specific vaccinations typically amplify the absolute number of such T cells, but may have little consequence on improving their functional avidity, which may fall below a critical threshold required for effective recognition of tumor cells in situ. This review will discuss methods to improve low-avidity T-cell recognition of cancer cells by manipulating the tumor cells themselves to conditionally express higher levels of TAA-derived peptide epitopes presented in major histocompatibility (MHC) complexes. This may facilitate the design and performance of novel combinational therapies for the effective treatment of a broad range of cancer types.

AB - Tumors represent an "altered" self cell type that can be recognized by both the host humoral (B cells, antibodies) and cellular (T cells) adaptive immune systems. "Because most known tumor-associated antigens (TAA) recognized by T cells represent overexpressed or aberrantly expressed proteins, which are not mutated and to which tolerance has been developed, the anti-TAA T-cell repertoire available to the cancer patient is of moderate-to-low avidity. Specific vaccinations typically amplify the absolute number of such T cells, but may have little consequence on improving their functional avidity, which may fall below a critical threshold required for effective recognition of tumor cells in situ. This review will discuss methods to improve low-avidity T-cell recognition of cancer cells by manipulating the tumor cells themselves to conditionally express higher levels of TAA-derived peptide epitopes presented in major histocompatibility (MHC) complexes. This may facilitate the design and performance of novel combinational therapies for the effective treatment of a broad range of cancer types.

KW - Antigen processing

KW - CD8+ T lymphocytes

KW - HSP90

KW - Proteasome

UR - http://www.scopus.com/inward/record.url?scp=38049043831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049043831&partnerID=8YFLogxK

M3 - Article

C2 - 18197809

AN - SCOPUS:38049043831

VL - 27

SP - 485

EP - 493

JO - Critical Reviews in Immunology

JF - Critical Reviews in Immunology

SN - 1040-8401

IS - 5

ER -